Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
you wrote:
I agree still pretty vague, but better than no communication.
I liked this:
My Condolences Gary.
you wrote:
I was not aware of that history, so thank you for your brief history overview lesson.
Must-pass user fee deals: Biopharma companies fund more than 80% of FDA's review staff.
https://endpts.com/must-pass-user-fee-deals-biopharma-companies-fund-more-than-80-of-fdas-review-staff-cder-head-tells-congress/
includes:
You wrote:
Biomedtech 2022 - Jan 27 2022. Page 20
I am not caught up with the most current posts, but I came across this article & thought I would share it. Sorry if someone else already posted it.
https://epaper.businessweekly.co.uk/html5/reader/production/default.aspx?pubname=&pubid=73060283-e40e-4de5-8fed-64ba0bf97eab
Sawston cell & gene therapy hothouse on exponential growth curve.
you wrote:
I believe it was my post 437843 which first brought attention to Stupp showing up with an advisory role to NWBO.
you wrote:
Sonobiopsy : I think this new technology may have a big impact on NWBO - DCVax-L ... future trial work (confirmatory?) and or (compassionate care) treatments for GBM as well as perhaps for cancers with inoperable tumors?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690937/
Theranostics. 2022; 12(1): 362–378.
Published online 2022 Jan 1. doi: 10.7150/thno.65597
PMCID: PMC8690937
PMID: 34987650
Sonobiopsy for minimally invasive, spatiotemporally-controlled, and sensitive detection of glioblastoma-derived circulating tumor DNA
includes:
You wrote, in regards to Flipper post 439347:
https://www.nejm.org/doi/full/10.1056/nejmoa043330
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
List of authors.
Roger Stupp, M.D., Warren P. Mason, M.D., Martin J. van den Bent, M.D., Michael Weller, M.D., Barbara Fisher, M.D., Martin J.B. Taphoorn, M.D., Karl Belanger, M.D., Alba A. Brandes, M.D., Christine Marosi, M.D., Ulrich Bogdahn, M.D., Jürgen Curschmann, M.D., Robert C. Janzer, M.D., et al., for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group*
March 10, 2005
N Engl J Med 2005; 352:987-996
DOI: 10.1056/NEJMoa043330
Professor Roger Stupp = Section Editor of the European Journal of Cancer.
Chinese Neurosurgical Journal - Glioblastoma vaccine tumor therapy research progress
Published: 19 January 2022
Tong Zhao, Chunwang Li, Hongliang Ge, Yuanxiang Lin & Dezhi Kang
Chinese Neurosurgical Journal volume 8, Article number: 2 (2022)
includes:
Impact of a Whole-Room Atomizing Disinfection System on Healthcare Surface Contamination, Pathogen Transfer, and Labor Efficiency
Reynolds, Kelly A. PhD1; Sexton, Jonathan D. PhD1; Garavito, Fernanda MPH1; Anderson, Brandie BS, RN, BSN, MPH, CIC2; Ivaska, Joan M. BS, MPH, CIC3
Author Information
Critical Care Explorations: February 2021 - Volume 3 - Issue 2 - p e0340
doi: 10.1097/CCE.0000000000000340
includes:
you wrote:
PCTL should try to obtain some additional funding from BR or MS or other, to wipe out any and all other remaining debt (with good terms of course), and consolidate the debt into just a small number of debt instruments (this would make the audit process a lot simpler too).
Look at what this crappy $75K loan resulted in & the risks & headaches of now having to try to pursue a settlement, and now having to pursue a lawsuit, which all distracts from the efficient running of the main business:
https://pctl.com/wp-content/uploads/2022/01/PCTL-01-20-22-8-K-filing.pdf
Auctus Fund Litigation
In March of 2019, we entered into a Securities Purchase Agreement with Auctus Fund, LLC (“Auctus”), whereby we borrowed $75,000 from Auctus under the terms of a convertible promissory note and included the issuance to 187,500 warrants to Auctus. Adjustment provisions in the Securities Purchase Agreement and the note required PCTL to adjust the number of warrants and exercise price based upon future financings.
In late 2019, we defaulted on the Auctus note, which triggered a number of default provisions of the note. We disputed the amounts claimed to be owed to Auctus, the number of shares of common stock to be reserved for conversion of the note and the number and exercise price of the
warrants held by Auctus. Negotiations of these disputes lasted for several months.
In October of 2020, we entered into a Conditional Settlement Agreement with Auctus to settle all disputes and claims between the parties. A material dispute between the parties was the warrants, which according the Auctus had ballooned to 107,142,857 shares at an exercise price of $0.00035.
Pursuant to the settlement agreement, Auctus agreed to settle such disputes and claims based upon the payment of $145,000 in cash and the issuance of 8,000,000 shares of common stock.
On September 1, 2021, we issued 8,000,000 common shares and paid the remaining cash balance to Auctus under the terms of the settlement. We fully complied with all payments required under the settlement agreement and issued the shares of common stock to Auctus, which triggered the mutual release of all disputes and claims between us and Auctus. Despite our compliance with the terms of the settlement agreement, Auctus has refused to execute the mutual release required by the settlement agreement and acknowledge the cancellation of the warrants as part of the settlement.
On January 14, 2022, we filed a complaint in the United States District Court for the District of Massachusetts (Case 1:22-cv-10053), against Auctus seeking damages for:
1. Breach of Contract;
2. Breach of Implied Covenant of Good Faith and Fair Dealing;
3. Reformation of Mutual Release;
4. Fraud;
5. Conversion; and
6. Unjust Enrichment.
The case is currently ongoing.
nope ... SP increased after the podcast ... leading up to the $0.08 - 0.09 SP.
Point being, that once Flaskworks gets incorporated into Sawston, then:
1. I believe they will not only manufacture dendritic cells, but also CAR-T cells.
2. I believe the Sawston facility may be used not only for cell manufacturing, (and ultra cold storage), but also preclinical research can take place there utilizing the Flaskworks system ... including for DCVax-Direct?
Flaskworks Shashi Murthy
around 1'17: there is another frontier altogether of using dendritic cells to prepare and manufacture exquisitely targeted T-cell therapies
around 3'12: Designing systems, not only for the manufacture of cell based therapies based on dendritic cells, but also automated systems that can be used for preclinical research.